Current campaigns

Have your say to support the PBS listing of Stelara for treatment of Crohn’s disease in adults                                  advocate_icon

Submissions due by 8th February 2017

Crohn’s & Colitis Australia urges its members to have their say about the potential listing of Stelara (Ustekinumab) on the Pharmaceutical Benefits Scheme (PBS) for the treatment of Crohn’s disease in adults.

Stelara’s inclusion on the PBS list offers patients another treatment option if the efficacy of other treatments diminishes.

The manufacturers of Stelara, a biologic therapy, have recently made an application to Pharmaceutical Benefits Advisory Committee (PBAC) for their product to be made available to patients through the PBS for the treatment of moderate to severe Crohn’s disease and ulcerative colitis.

PBS is the main mechanism via which the Government subsidises the cost of medications used by the community. Stelara is not currently available through the PBS, making it prohibitively expensive for most Australians.

As part of its evaluation of products the PBAC asks for public comments from patients, carers, members of the public, health professionals or consumer interest groups.  These comments help the PBAC assess if the community needs access to this therapy.

If you have lived experience using Stelara, we encourage you to have your say and support this treatment being made available through subsidy on the PBS.


Have  your say and let the PBS know your needs for treatment of ulcerative colitis

Submissions closed



Have  your say and support the PBS listing of Humira for treatment of Ulcerative Colitis

Submissions closed

Have your say about getting Vedolizumab on the PBS listing for treatment of Crohn’s disease and ulcerative colitis! 

Submissions closed

Have your say and support the PBS listing of Humira for treatment of paediatric Crohn’s!

Submissions closed

Improving IBD care across Australia

PwC ReportAustralia is part of a global movement to improve the quality of IBD care throughout the world.

A recent report, Improving Inflammatory Bowel Disease Care Across Australia found that IBD care was recommended CCA seek funding of approximately $1 million over two years to construct an evidence base from which to develop nationally consistent responses for improved IBD care.

In December 2013 the Federal Government agreed to match every dollar raised by CCA (up to $500,000) for a landmark program to improve the quality of IBD care. Donate today.

To find out more, please contact us on 1800 138 029.